Sudden cardiac death (SCD) secondary to sudden cardiac arrest (SCA) is a leading cause
of death in the United States, claiming over a quarter million lives annually, and
is directly responsible for 50% of all cardiovascular mortality. Brugada Syndrome
(BrS) is an arrhythmogenic cardiovascular channelopathy that predisposes asymptomatic
patients who have no identified disease to a high-risk of SCD/SCA as their first cardiac
event/disease manifestation. Limited progress has been made in risk prediction of
SCA and SCD, with the greatest challenge being the ability to identify the small high-risk
subgroups concealed within the larger general population. In conclusion, accurate
identification of high-risk asymptomatic BrS patients (through multiparametric risk
scores composed of reliable and validated unambiguous clinical variables and biomarkers)
may hold utility in improving current SCD prediction algorithms, and the appropriate
primary prevention therapy may prove valuable in reducing risk of sudden death for
this patient population. This systematic review aims to comprehensively summarize
qualitative evidence that explore proposed clinical, electrocardiographic, electrophysiological,
and genetic markers for risk stratification of patients with BrS phenotype, and to
discuss the best available contemporary evidence regarding therapeutic approach.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Circulation. 2018; 138: e272-e391
- Genetics of Brugada syndrome.J Hum Genet. 2016; 61: 57-60
- Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.Europace. 2013; 15: 1389-1406
- Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry.Circulation. 2010; 121: 635-643
- Natural history of Brugada syndrome: insights for risk stratification and management.Circulation. 2002; 105: 1342-1347
- Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome.Eur Heart J. 2007; 28: 334-344
- Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.Circulation. 2005; 111: 659-670
- Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome.J Am Coll Cardiol. 1992; 20: 1391-1396
- Proposed diagnostic criteria for the Brugada syndrome: consensus report.Circulation. 2002; 106: 2514-2519
- 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).Eur Heart J. 2015; 36: 2793-2867
- Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population.Eur Heart J. 2004; 25: 874-878
- Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study.Europace. 2009; 11: 507-513
- Gender differences in clinical manifestations of Brugada syndrome.J Am Coll Cardiol. 2008; 52: 1567-1573
- Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.Circulation. 2013; 128: 1739-1747
- Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.J Am Coll Cardiol. 2012; 59: 37-45
- The prognostic value of early repolarization (J wave) and ST-segment morphology after J wave in Brugada syndrome: multicenter study in Japan.Heart Rhythm. 2013; 10: 533-539
- The prognostic impact of single extra-stimulus on programmed ventricular stimulation in Brugada patients without previous cardiac arrest: multi-centre study in Japan.Europace. 2018; 20: 1194-1200
- Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach.Eur Heart J. 2011; 32: 169-176
- A clinical score model to predict lethal events in young patients (</=19 Years) with the Brugada syndrome.Am J Cardiol. 2017; 120: 797-802
- Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3.Circ Arrhythm Electrophysiol. 2009; 2: 495-503
- Long-term trends in newly diagnosed Brugada syndrome: implications for risk stratification.J Am Coll Cardiol. 2016; 68: 614-623
- A new electrocardiographic marker of sudden death in Brugada syndrome: the S-wave in lead I.J Am Coll Cardiol. 2016; 67: 1427-1440
- Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: potential diagnostic and prognostic implications.Heart Rhythm. 2017; 14: 866-874
- The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk.Heart Rhythm. 2017; 14: 1147-1154
- Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries.J Am Coll Cardiol. 2013; 61: 2383-2387
- A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.N Engl J Med. 1997; 337: 1576-1583
- Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study.Eur Heart J. 2000; 21: 2071-2078
- Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications.Heart Rhythm. 2016; 13: 443-454
- Patients with Brugada syndrome and implanted cardioverter-defibrillators: long-term follow-up.J Am Coll Cardiol. 2017; 70: 1991-2002
Article info
Publication history
Published online: September 09, 2019
Received in revised form:
August 16,
2019
Received:
June 28,
2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
